Nouhad Husseini
Director/Board Member bei DECIBEL THERAPEUTICS, INC.
Aktive Positionen von Nouhad Husseini
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2011 | - |
| CHECKMATE PHARMACEUTICALS, INC. | Director/Board Member | 31.05.2022 | - |
| Corporate Officer/Principal | 31.05.2022 | - | |
| DECIBEL THERAPEUTICS, INC. | Director/Board Member | 22.09.2023 | - |
| Corporate Officer/Principal | 22.09.2023 | - |
Karriereverlauf von Nouhad Husseini
Ausbildung von Nouhad Husseini
| Princeton University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Nouhad Husseini
- Erfahrung
